Prognostic importance of baseline and serial glycated hemoglobin levels in high-risk patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study

Acta Diabetologica

Volumn 52, Issue 1, 2015, Pages 21-29

  Cardoso, Claudia R L ^a   Leite, Nathalie C ^a   Ferreira, Marcel T ^a   Salles, Gil F ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Cardiovascular outcomes; Glycated hemoglobin; Prognosis; Type 2 diabetes

Indexed keywords

GLYCOSYLATED HEMOGLOBIN;

AGED; BLOOD; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; COMPLICATION; FEMALE; FOLLOW UP; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; RISK FACTOR; SURVIVAL;

AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SURVIVAL;

EID: 84938761248     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-014-0592-0     Document Type: Article

References (31)

1. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–1053
2. Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829–841
3. Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW (2005) Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 165:1910–1916
4. Andersson C, van Gaal L, Caterson ID, Weeke P, James WP, Coutinho W et al (2012) Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. Diabetologia 55:2348–2355
5. Zhao W, Katzmarzyk PT, Horswell R, Wang Y, Johnson J, Hu G (2014) HbA1c and coronary heart disease risk among diabetic patients. Diabetes Care 37:428–435
6. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH (2004) Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141:421–431
7. Zhang Y, Hu G, Yuan Z, Chen L (2012) Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One 7:e42551
8. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853
9. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865
10. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559
11. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572
12. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, VADT Investigators et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139
13. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589
14. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D et al (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373:1765–1772
15. Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J (2009) Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 151:394–403
16. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal TP, Hemmingsen C, Wetterslev J (2013) Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 11:CD008143
17. Yudkin JS, Richter B, Gale EA (2010) Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 53:2079–2085
18. Ferguson LD, Sattar N (2013) Reducing cardiovascular disease risk in type 2 diabetes: is the focus on glycaemia warranted? Diabetes Obes Metab 15:387–391
19. Salles GF, Leite NC, Pereira BB, Nascimento EM, Cardoso CR (2013) Prognostic impact of clinic and ambulatory blood pressure components in high-risk type 2 diabetic patients: the Rio de Janeiro Type 2 Diabetes Cohort Study. J Hypertens 31:2176–2186
20. Cardoso CR, Leite NC, Ferreira MT, Salles GF (2013) Prognostic impact of aortic stiffness in high-risk type 2 diabetic patients: the Rio de Janeiro Type 2 Diabetes Cohort Study. Diabetes Care 36:3772–3778
21. Cardoso CR, Marques CE, Leite NC, Salles GF (2012) Factors associated with carotid intima-media thickness and carotid plaques in type 2 diabetic patients. J Hypertens 30:940–947
22. American Diabetes Association (2005) Standards of medical care in diabetes. Diabetes Care 28(suppl 1):S4–S36
23. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412
24. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL et al (2010) Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 375:481–489
25. Landman GW, van Hateren KJ, Kleefstra N, Groenier KH, Gans RO, Bilo HJ (2010) The relationship between glycaemic control and mortality in patients with type 2 diabetes in general practice (ZODIAC-11). Br J Gen Pract 60:172–175
26. Khunti K, Weston C, Gholap N, Molokhia M, Paul S, Millett C et al (2013) All-cause mortality in relation to glycated haemoglobin in individuals with newly diagnosed type 2 diabetes: a retrospective cohort study. Br J Diab Vasc Dis 13:22–30
27. Greenfield S, Billimek J, Pellegrini F, Franciosi M, De Berardis G, Nicolucci A, Kaplan SH (2009) Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study. Ann Intern Med 151:854–860
28. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, Action to Control Cardiovascular Risk in Diabetes Investigators et al (2010) Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 33:983–990
29. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA et al (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 119:351–357
30. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:1364–1379
31. American Diabetes Association (2014) Standards of medical care in diabetes. Diabetes Care 37(suppl 1):S14–80